Michael Krevolin, DO
Family Medicine · Langhorne, PANPI 1013398114
Payments from drug & device makers
Across 156 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$700
- Lilly USA, LLC$427
- AbbVie$244
- AstraZeneca$194
- Exact Sciences$140
- Merck$109
- plus $753 from 22 others
What the payments were for
- Food & beverage$2,558100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $700 |
| Lilly USA, LLC | 25 | $427 |
| AbbVie | 15 | $244 |
| AstraZeneca | 13 | $194 |
| Exact Sciences | 7 | $140 |
| Merck | 8 | $109 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| Amarin Pharma, Inc. | 5 | $67 |
| Abbott | 3 | $64 |
| Amgen | 3 | $57 |
| Pfizer | 3 | $53 |
| Bayer | 3 | $51 |
| Lundbeck LLC | 2 | $43 |
| Bausch Health US, LLC | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Corcept Therapeutics | 2 | $31 |
| Eisai Inc. | 2 | $30 |
| Boehringer Ingelheim | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 2 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| GSK | 1 | $21 |
| Edwards Lifesciences | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Almatica Pharma LLC | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $15 |
| Novartis | 1 | $12 |
How this compares
$2,567 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 26 | $26,459 |
| EliquisApixaban | 17 | $15,313 |
| FarxigaDapagliflozin Propanediol | 17 | $14,138 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $10,793 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,372 |
| EntrestoSacubitril/Valsartan | 13 | $8,607 |
| Alendronate Sodium | 18 | $2,369 |
| Rosuvastatin Calcium | 148 | $2,322 |
| Atorvastatin Calcium | 132 | $1,535 |
| Levothyroxine Sodium | 79 | $1,248 |
| SynthroidLevothyroxine Sodium | 17 | $1,100 |
| Fluticasone Propionate | 33 | $1,071 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $1,011 |
| Montelukast Sodium | 78 | $869 |
| Metoprolol Succinate | 53 | $864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $427 | $26,45926 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $21 | $20,16529 claims |
| PfizerEliquis | $53 | $15,31317 claims |
| AstraZenecaFarxiga | $194 | $14,13817 claims |
| NovartisEntresto | $12 | $8,60713 claims |
| AbbVieSynthroid | $244 | $1,10017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Langhorne
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.